Background:Restless Leg Syndrome (RLS) has a major impact on the quality of life and requires innovative approaches to improve symptom management. This study focuses on the design and development of Ropinirole-loaded nanoparticles for targeted intranasal delivery to enhance therapeutic outcomes in RLS patients.Materials and Methods:Ropinirole, a dopamine agonist, was incorporated into chitosan nanoparticles with the help of the Box-Behnken design (BBD) to optimize key parameters such as particle size, polydispersity index (PDI), entrapment efficiency of the drug, and drug release kinetics. Characterization of the nanoparticles involved Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and other common techniques. Intranasal delivery was selected to circumvent the blood-brain barrier and deliver the drug across the nasal epithelial lining into the central nervous system.Results:The optimized nanoparticles had desirable physicochemical properties: sustained drug release, high entrapment efficiency, and thermal stability. These nanoparticles exhibited significant potential to reduce symptoms in RLS patients and minimize systemic side effects in the preclinical assessments.Conclusion:The current study points to the potential of Ropinirole-loaded nanoparticles as a delivery system for treating RLS. Further clinical studies are warranted to confirm these results and establish both short- and long-term safety and efficacy.